日本重症监护患者数据库中多巴胺的使用及其后果:一项队列研究
该研究利用日本最大的重症监护数据库JIPAD,纳入18岁以上、非手术原因入ICU、ICU停留≥24小时且在入ICU 24小时内使用多巴胺或去甲肾上腺素的14494例患者,其中多巴胺组4453例、去甲肾上腺素组11844例。多因素分析显示,多巴胺剂量≤5 μg/kg/min组住院死亡OR为0.86(95%CI 0.71-1.04),5-15 μg/kg/min组OR为1.46(95%CI 1.18-1.82),>15 μg/kg/min组OR为3.30(95%CI 1.19-9.19)。1:1倾向性评分匹配(570对)后,多巴胺组住院死亡率22.5% vs 17.4%(p=0.038),ICU死亡率13.3% vs 8.8%(p=0.018),ICU住院时间平均9.3天 vs 7.4天(p=0.004)。作者认为高剂量多巴胺可能带来不良后果。
要点
- 日本56个中心14494例ICU患者中,4453例使用多巴胺、11844例使用去甲肾上腺素,多巴胺仍广泛使用。
- 多因素分析:多巴胺≤5 μg/kg/min组住院死亡OR 0.86(95%CI 0.71-1.04),5-15 μg/kg/min组OR 1.46(95%CI 1.18-1.82),>15 μg/kg/min组OR 3.30(95%CI 1.19-9.19)。
- 1:1倾向性评分匹配570对后,多巴胺组住院死亡率22.5% vs 无多巴胺组17.4%(p=0.038),ICU死亡率13.3% vs 8.8%(p=0.018)。
- 匹配后多巴胺组ICU住院时间平均9.3天 vs 无多巴胺组7.4天(p=0.004)。
- 多巴胺组较去甲肾上腺素组更多心血管诊断(70% vs 42%,p<0.01)、更多择期术后状态(60% vs 31%)、APACHE III评分更低(70.7 vs 83.0,p<0.01)。
适用人群与场景
- 纳入标准:年龄18岁或以上;因非操作原因入住ICU;ICU停留时间24小时或以上;入ICU 24小时内接受多巴胺或去甲肾上腺素治疗。
- 数据来源为日本重症监护患者数据库(JIPAD),共纳入56个中心的14594例记录。
研究设计与关键结果
- 研究类型为基于JIPAD数据库的队列研究,纳入14594例来自56个中心的患者,多巴胺组4453例、去甲肾上腺素组11844例。
- 主要终点为住院死亡率:多因素分析显示多巴胺≤5 μg/kg/min组OR 0.86(95%CI 0.71-1.04),5-15 μg/kg/min组OR 1.46(95%CI 1.18-1.82),>15 μg/kg/min组OR 3.30(95%CI 1.19-9.19)。
- 1:1倾向性评分匹配(570对)后,多巴胺组住院死亡率22.5% vs 无多巴胺组17.4%(p=0.038),ICU死亡率13.3% vs 8.8%(p=0.018)。
- 匹配后多巴胺组ICU住院时间平均9.3天 vs 无多巴胺组7.4天(p=0.004)。
- 多巴胺组与去甲肾上腺素组比较:心血管诊断70% vs 42%(p<0.01),择期术后状态60% vs 31%,APACHE III评分70.7 vs 83.0(p<0.01)。
- 频繁使用多巴胺的机构(N=28)与不频繁使用机构(N=28)之间机构特征无统计学显著差异。
证据类型、等级与局限
- 证据类型:基于日本重症监护患者数据库(JIPAD)的队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,研究结果提示高剂量多巴胺可能带来不良后果。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Dopamine is used to treat patients with shock in intensive care units (ICU) throughout the world, despite recent evidence against its use. The aim of this study was to identify the latest practice of dopamine use in Japan and also to explore the consequences of dopamine use in a large Asian population.
METHODS: The Japanese Intensive Care PAtient Database (JIPAD), the largest intensive care database in Japan, was utilized. Inclusion criteria included: 1) age 18 years or older, 2) admitted to the ICU for reasons other than procedures, 3) ICU length of stay of 24 h or more, and 4) treatment with either dopamine or noradrenaline within 24 h of admission. The primary outcome was in-hospital mortality. Multivariable regression analysis was performed, followed by a propensity score-matched analysis.
RESULTS: Of the 132,354 case records, 14,594 records from 56 facilities were included in this analysis. Dopamine was administered to 4,653 patients and noradrenaline to 11,844. There was no statistically significant difference in facility characteristics between frequent dopamine users (N = 28) and infrequent users (N = 28). Patients receiving dopamine had more cardiovascular diagnosis codes (70% vs. 42%; p < 0.01), more post-elective surgery status (60% vs. 31%), and lower APACHE III scores compared to patients given noradrenaline alone (70.7 vs. 83.0; p < 0.01). Multivariable analysis showed an odds ratio for in-hospital mortality of 0.86 [95% CI: 0.71-1.04] in the dopamine ≤ 5 μg/kg/min group, 1.46 [95% CI: 1.18-1.82] in the 5-15 μg/kg/min group, and 3.30 [95% CI: 1.19-9.19] in the > 15 μg/kg/min group. In a 1:1 propensity score matching for dopamine use as a vasopressor (570 pairs), both in-hospital mortality and ICU mortality were significantly higher in the dopamine group compared to no dopamine group (22.5% vs. 17.4%, p = 0.038; 13.3% vs. 8.8%, p = 0.018), as well as ICU length of stay (mean 9.3 days vs. 7.4 days, p = 0.004).
CONCLUSION: Dopamine is still widely used in Japan. The results of this study suggest detrimental effects of dopamine use specifically at a high dose. Trial registration Retrospectively registered upon approval of the Institutional Review Board and the administration office of JIPAD.
参考来源
- Suzuki R, Uchino S, Sasabuchi Y, et al. Dopamine use and its consequences in the intensive care unit: a cohort study utilizing the Japanese Intensive care PAtient Database. Crit Care. 2022. PMID: 35366934. doi:10.1186/s13054-022-03960-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。